23/02/2021 at 12:13 PM #25908Anonymous UserParticipant
Consensus on astrocytes, neglected partners of neurons in brain disease
The change of astrocytes into reactive astrocytes is a mechanism common to many diseases affecting the central nervous system. Yet this answer remains poorly understood and is the subject of confusion and controversy. In this article published as the first “in the review , 81 researchers from 22 agree on the definitions and nomenclature of reactive astrocytes. They analyze some simplistic conceptions and debates about these cells and give recommendations for future research in this area.
In the brain, astrocytes are essential partners for neurons and they have an active role in the functioning and plasticity of the brain. In response to a pathological (infection, , , , or during neurodegenerative diseases such as Alzheimer’s), these cells change, we say that the astrocytes have become “reactive”. Given their many roles for the cerebral, transformation into reactive astrocytes is likely to have important consequences on the resilience of the brain to each pathological situation and to influence the course of the disease.
While this significant transformation of astrocytes was observed over a hundred years ago in the brains of patients with different brain pathologies, many aspects remain either misunderstood or controversial.
More than 80 international experts working on astrocytes exchanged points of for one year, to establish common recommendations on nomenclature, good and the important questions to be explored to better understand the complex and specific responses of astrocytes in pathological conditions.
This community consensus effort working on astrocytes ultimately aims to optimize targeting reactive astrocytes in each , but also to use reactive astrocytes as biomarkers for the , monitoring the evolution of brain diseases and stratification of patients.
To know more:
Reactive astrocyte nomenclature, definitions, and future directions.
Escartin C, Galea E, Lakatos A, O’Callaghan JP, Petzold GC, Serrano-Pozo A, Steinhäuser C, Volterra A, Carmignoto G, Agarwal A, Allen NJ, Araque A, Barbeito L, Barzilai A, Bergles DE, Bonvento G, Butt AM, Chen WT, Cohen-Salmon M, Cunningham C, Deneen B, De Strooper B, Díaz-Castro B, Farina C, Freeman M, Gallo V, Goldman JE, Goldman SA, Götz M, Gutiérrez A, Haydon PG, Heiland DH, Hol EM, Holt MG, Iino M, Kastanenka KV, Kettenmann H, Khakh BS, Koizumi S, Lee CJ, Liddelow SA, MacVicar BA, Magistretti P, Messing A, Mishra A, Molofsky AV, Murai KK, Norris CM, Okada S, Oliet SHR, Oliveira JF, Panatier A, Parpura V, Pekna M, Pekny M, Pellerin L, Perea G, Pérez-Nievas BG, Pfrieger FW, Poskanzer KE, Quintana FJ, Ransohoff RM, Riquelme-Perez M, Robel S, Rose CR, Rothstein JD, Rouach N, Rowitch DH, Semyanov A, Sirko S, Sontheimer H, Swanson RA, Vitorica J, Wanner IB, Wood LB, Wu J, Zheng B, Zimmer ER, Zorec R, Sofroniew MV, Verkhratsky A.
Nature Neuroscience. February 15, 2021. doi: 10.1038 / s41593-020-00783-4.
Laboratory for Neurodegenerative Diseases – MIRCen (LMN) (CNRS / CEA / Univ. Paris-Saclay) – 18, of Panorama. – 92265 Fontenay-aux-roses Cedex. – France.
Carole Escartin – Researcher at the Neurodegenerative Diseases Laboratory – carole.escartin at cea.fr
- You must be logged in to reply to this topic.